Biogen drug slows progress of motor neurone disease in landmark trial

Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news